Show simple item record

dc.contributor.authorBriassoulis, E. Chen
dc.contributor.authorAndreopoulou, E.en
dc.contributor.authorCh, F. Tolisen
dc.contributor.authorBairaktari, Eleni Then
dc.contributor.authorKatsaraki, A.en
dc.contributor.authorDimopoulos, M. A.en
dc.contributor.authorFountzilas, Georgeen
dc.contributor.authorSeferiadis, C.en
dc.contributor.authorPavlidis, Nicholasen
dc.creatorBriassoulis, E. Chen
dc.creatorAndreopoulou, E.en
dc.creatorCh, F. Tolisen
dc.creatorBairaktari, Eleni Then
dc.creatorKatsaraki, A.en
dc.creatorDimopoulos, M. A.en
dc.creatorFountzilas, Georgeen
dc.creatorSeferiadis, C.en
dc.creatorPavlidis, Nicholasen
dc.date.accessioned2018-06-22T09:52:43Z
dc.date.available2018-06-22T09:52:43Z
dc.date.issued2001
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/41471
dc.description.abstractBACKGROUND. Cancer antigen 15-3 (CA 15-3), a circulating marker that determines secreted products of the polymorphic MUC1 gene, has been established as a convenient tool for monitoring breast carcinoma patients. METHODS. The authors investigated alterations of soluble CA 15-3 in 57 postoperative breast carcinoma patients while they were receiving intensified adjuvant chemotherapy with granulocyte colony stimulating factor (G-CSF) support: 26 patients had American Joint Committee on Cancer (AJCC) Stage 11, and 31 patients had AJCC Stage III breast carcinoma. Serial CA 15-3 values recorded thoughout the treatment were compared with baseline values, analyzed for correlation with hematologic and biochemical parameters, and compared with clinicopathologic characteristics and patient outcome. At a median follow-up time of 32 months, 47 of these patients remained relapse-free. RESULTS. A twofold increase of CA 15-3 was detected at the end of the second week of treatment, remained significantly elevated in most patients at above the cutoff level of 30 U/mL throughout the treatment period (P < 0.0001), and subsided to pretreatment values 1-2 months after treatment cessation. CA 15-3 values were found to be associated strongly with absolute neutrophil count, serum lactate dehydrogenase, and alkaline phosphatase. The median values and the kinetics of tumor markers did not differ over time in regard to hormonal receptor status and disease recurrence. CONCLUSIONS. These data provide strong evidence that G-CSF administration can induce elevation of CA 15-3 and indicate that false-positive results should be considered when evaluating CA 15-3 in patients who are receiving G-CSF. It is speculated that this phenomenon occurs through the induction of MUC1 antigen of unknown origin by G-CSF. Experimental investigation of this clinical observation is warranted. © 2001 American Cancer Society.en
dc.language.isoengen
dc.sourceCanceren
dc.subjectArticleen
dc.subjectFemaleen
dc.subjectCyclophosphamideen
dc.subjectFluorouracilen
dc.subjectHumanen
dc.subjectMethotrexateen
dc.subjectAgeden
dc.subjectHumansen
dc.subjectAdulten
dc.subjectBreast neoplasmsen
dc.subjectMajor clinical studyen
dc.subjectMiddle ageden
dc.subjectPaclitaxelen
dc.subjectPriority journalen
dc.subjectAntineoplastic combined chemotherapy protocolsen
dc.subjectCancer recurrenceen
dc.subjectGranulocyte colony-stimulating factoren
dc.subjectCancer stagingen
dc.subjectTreatment outcomeen
dc.subjectEpirubicinen
dc.subjectCarcinomaen
dc.subjectGeneen
dc.subjectDna polymorphismen
dc.subjectBreast carcinomaen
dc.subjectCancer adjuvant therapyen
dc.subjectAdjuvant chemotherapyen
dc.subjectAlkaline phosphataseen
dc.subjectBiologicalen
dc.subjectCa-15-3 antigenen
dc.subjectCancer antigen 15-3en
dc.subjectEnzyme blood levelen
dc.subjectFalse positive reactionsen
dc.subjectGranulocyte colony stimulating factoren
dc.subjectIntensified chemotherapyen
dc.subjectLactate dehydrogenaseen
dc.subjectMuc1en
dc.subjectPatient monitoringen
dc.subjectPostoperative perioden
dc.subjectTumor markersen
dc.titleG-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant settingen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1002/1097-0142(20010301)91:5<909
dc.description.volume91
dc.description.issue5
dc.description.startingpage909
dc.description.endingpage917
dc.author.facultyΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]
dc.gnosis.orcid0000-0002-2195-9961


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record